Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2645447 | 0.91 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1KMT2ATDP1 | |
| SCHEMBL12159688 | 0.87 | KMT2A (0.58) | ALDH1A1MAPK1L3MBTL1KMT2ATDP1 | |
| SCHEMBL13748438 | 0.87 | NPC1 (0.62) | ALDH1A1MAPK1L3MBTL1KMT2ATDP1 | |
| SCHEMBL10252731 | 0.87 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1KMT2ATDP1 | |
| SCHEMBL28488994 | 0.86 | ERCC5 (0.60) | ALDH1A1MAPK1L3MBTL1NR4A1NR4A2 | |
| SCHEMBL5754659 | 0.86 | RAB9A (0.59) | ALDH1A1MAPK1L3MBTL1KMT2ATDP1 | |
| SCHEMBL294341 | 0.82 | ALDH1A1 (0.73) | ALDH1A1MAPK1L3MBTL1KMT2ATDP1 | |
| SCHEMBL224663 | 0.81 | ALDH1A1 (0.79) | ALDH1A1MAPK1L3MBTL1NR4A1NR4A2 | |
| SCHEMBL5751558 | 0.80 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1KMT2ATDP1 | |
| SCHEMBL8069055 | 0.80 | ALDH1A1 (0.70) | ALDH1A1MAPK1L3MBTL1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294633-B2 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2007-11-13 | — | — | US | disclosed |
| EP-1390371-B1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | NOVARTIS AG (CH) | 2006-03-08 | — | — | EP | disclosed |
| US-20040152892-A1 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2004-08-05 | — | — | US | disclosed |
| EP-1390371-A1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | Novartis AG (CH) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002092603-A1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152892-A1 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | DPYD, COXFA4L2, MSH2 | ALDH1A1 122/4885MAPK1 1933/4885L3MBTL1 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.